Investors

Large and Growing Market Opportunity
The global CF market was $5.75 billion in 2021 and is expected to grow at 24.3% CAGR through 2030, creating strong demand for curative therapies.

Addressing an Urgent Medical Need
Our lead program, GEN-023, is specifically designed for the final 10% of CF patients (~3,000 in the U.S.) who cannot benefit from existing treatments– representing a critical, underserved population​.

Proven Technology with Clinical Precedent
A Phase 1 clinical trial using a related delivery system demonstrated no serious adverse events (SAEs) and clinically significant CFTR function restoration– providing a strong foundation for GEN-023’s success​.

Breakthrough Gene Therapy Platform
Our non-viral, non-LNP GeneZip system overcomes the limitations of traditional gene therapy, allowing for repeat dosing, enhanced delivery, and long-term safety​.

Strong Financial & Strategic Backing
Backed by Orange Grove Bio support from the NIH (NHLBI), we are well-positioned to accelerate preclinical development and first-in-human trials.

Beyond CF—A Scalable Gene Therapy Platform
The GeneZip platform extends beyond CF, with broad applications in neurological and large-gene diseases. Preclinical studies have already demonstrated long-term gene expression in a variety of tissues, opening doors for multiple high-value indications.